MomentUM

Seminar

Jesse Berry, MD. FACS

Chief of Ophthalmology, Director of the Vision Center, and Director of the Ocular Oncology and Retinoblastoma Programs at Children's Hospital Los Angeles
Professor, Ophthalmology, Radiation Oncology, Dermatology at University of Southern California

Exploration of Aqueous Biomarkers from Retinoblastoma to Uveal Melanoma

Over the past decade, aqueous humor liquid biopsy has emerged as a transformative tool in ocular oncology, enabling minimally invasive molecular profiling of intraocular tumors from small-volume aqueous samples. Pioneered in retinoblastoma, this work demonstrated that cell-free DNA and ctDNA correlate with disease activity and prognosis, and that RB1 mutations can be reliably tracked across treatment — findings that established the clinical foundation for the LBSeq4Kids platform. Serial aqueous sampling has since proven valuable for guiding therapy and identifying patients at risk for metastatic progression without systemic biopsy. Now, this liquid biopsy framework is being extended to uveal melanoma, where modeled aqueous humor protein concentrations are opening a new avenue for biomarker discovery and non-invasive disease characterization.

Invited by: The Uveal Melanoma Medico-Scientific Program, Institut Curie
Contact: leanne.de-koning@curie.fr

Monday June 29th 2026

5:15 pm CEST (11:15 am EDT; 8:15 am PDT)

Institut Curie, Amphitheater BDD, 11 rue Pierre et Marie Curie, Paris

The seminar will be broadcast online via Teams*

*Full Teams link: https://teams.microsoft.com/meet/32850157888167?p=Jt3dNzOIAQWv4T4UbN